368 related articles for article (PubMed ID: 25174315)
21. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Sanchez E; Li M; Steinberg JA; Wang C; Shen J; Bonavida B; Li ZW; Chen H; Berenson JR
Br J Haematol; 2010 Feb; 148(4):569-81. PubMed ID: 19958357
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.
Song IS; Kim HK; Lee SR; Jeong SH; Kim N; Ko KS; Rhee BD; Han J
Int J Cancer; 2013 Sep; 133(6):1357-67. PubMed ID: 23463417
[TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
25. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
[TBL] [Abstract][Full Text] [Related]
26. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
27. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Berkers CR; Verdoes M; Lichtman E; Fiebiger E; Kessler BM; Anderson KC; Ploegh HL; Ovaa H; Galardy PJ
Nat Methods; 2005 May; 2(5):357-62. PubMed ID: 15846363
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R; Davidson T
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
[TBL] [Abstract][Full Text] [Related]
29. Carfilzomib for the treatment of multiple myeloma.
Lue J; Goel S; Mazumder A
Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
[TBL] [Abstract][Full Text] [Related]
30. Dissecting bortezomib: development, application, adverse effects and future direction.
Cao B; Li J; Mao X
Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
Guan M; Zhu L; Somlo G; Hughes A; Zhou B; Yen Y
Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
[TBL] [Abstract][Full Text] [Related]
33. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
Neznanov N; Komarov AP; Neznanova L; Stanhope-Baker P; Gudkov AV
Oncotarget; 2011 Mar; 2(3):209-21. PubMed ID: 21444945
[TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib for previously untreated multiple myeloma.
Delforge M
Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Cavo M
Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
[TBL] [Abstract][Full Text] [Related]
37. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
[TBL] [Abstract][Full Text] [Related]
38. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
Zhen YZ; Lin YJ; Liu XJ; Shang BY; Zhen YS
Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252
[TBL] [Abstract][Full Text] [Related]
39. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
[TBL] [Abstract][Full Text] [Related]
40. Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Niewerth D; Jansen G; Assaraf YG; Zweegman S; Kaspers GJ; Cloos J
Drug Resist Updat; 2015 Jan; 18():18-35. PubMed ID: 25670156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
